Drug compliance – a pitfall of therapy of rheumatoid arthritis?

Česká verzia

Authors: L. Hromádková ¹; T. Soukup ²; J. Vlček ¹
Authors place of work: Katedra sociální a klinické farmacie Farmaceutické fakulty UK Hradec Králové, vedoucí prof. RNDr. Jiří Vlček, CSc. ¹; II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc. ²
Published in the journal: Vnitř Lék 2012; 58(9): 654-658
Category: Reviews

Summary

Drug compliance is one of the conditions for effective treatment of various chronic diseases, including rheumatoid arthritis as well. This disease is characterized by a variable course, remissions and relapses, and also by specific treatment. The character of this illness and used medications may represent a risk in terms of non-compliance. As in other chronic diseases, scientists engage in identifying of the compliance rate for many years and the aim of this work is to summarize the state of knowledge in the field of drug compliance in rheumatoid arthritis.

Key words:
drug compliance – adherence – rheumatoid arthritis

Zdroje

1. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964–975.

2. Vytřísalová M. Adherence k medikamentózní léčbě – známá neznámá. Remedia 2009; 19: 225–230.

3. de Klerk E, van der Heijde D, van der Tempel H et al. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol 1999; 26: 2635–2641.

4. de Klerk E, van der Heijde D, Landewé R et al. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003; 30: 2469–2475.

5. van den Bemt BJ, van den Hoogen FH, Benraad B et al. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 2009; 36: 2164–2170.

6. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008; 27: 883–889.

7. de Thurah A, Nørgaard M, Harder I et al. Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheumatol Int 2010; 30: 1441–1448.

8. Vermeire E, Hearnshaw H, Van Royen P et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26: 331–342.

9. Park DC, Hertzog C, Leventhal H et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc 1999; 47: 172–183.

10. Tuncay R, Eksioglu E, Cakir B et al. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int 2007; 27: 743–746.

11. Viller F, Guillemin F, Briançon S et al. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 1999; 26: 2114–2122.

12. Owen SG, Friesen WT, Roberts MS et al. Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br J Rheumatol 1985; 24: 313–320.

13. Lee P, Tan LJ. Drug compliance in outpatients with rheumatoid arthritis. Aust N Z J Med 1979; 9: 274–277.

14. Müller R, Kallikorm R, Põlluste K et al. Compliance with treatment of rheumatoid arthritis. Rheumatol Int 2011. Epub ahead of print.

15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487–497.

16. DiMatteo MR, Giordani PJ, Lepper HS et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794–811.

17. Pullar T, Peaker S, Martin MF et al. The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Br J Rheumatol 1988; 27: 381–384.

18. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003; 9 (Suppl 6): S136–S143.

19. Horne R, Weinman J. Patients‘ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555–567.

20. Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care 2001; 10: 135–140.

21. Beck NC, Parker JC, Frank RG et al. Patients with rheumatoid arthritis at high risk for noncompliance with salicylate treatment regimens. J Rheumatol 1988; 15: 1081–1084.

22. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization 2003.

23. Doyle DV, Perrett D, Foster OJ et al. The long-term use of D-penicillamine for treating rheumatoid arthritis: is continuous therapy necessary? Br J Rheumatol 1993; 32: 614–617.

24. de Klerk E, van der Heijde D, Landewé R et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003; 30: 44–54.

25. Wendling D, Materne GE, Michel F et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 2005; 72: 309–312.

26. Grijalva GC, Chung CP, Arbogast PG et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007; 45 (10 Suppl 2): S66–S76.

27. Taal E, Rasker JJ, Seydel ER et al. Health status, adherence with health recommendations, self-efficacy and social support in patients with rheumatoid arthritis. Patient Educ Couns 1993; 20: 63–76.